<DOC>
	<DOCNO>NCT03098797</DOCNO>
	<brief_summary>A randomized double-blind cross trial evaluate safety , efficacy tolerability elamipretide subject Barth Syndrome .</brief_summary>
	<brief_title>A Trial Evaluate Safety , Tolerability Efficacy Elamipretide Subjects With Barth Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Barth Syndrome</mesh_term>
	<criteria>Genetically confirm Barth Syndrome Male age 12 At screen visit , eGFR must meet following : 1 . Body weight &gt; 30 kg AND eGFR &gt; 90mL/min screen 2 . Body weight &gt; 40kg AND eGFR &gt; 60 &lt; 90mL/min screen Ambulatory impair 6MWT On stable medication 30 day prior baseline visit Participated another interventional clinical trial within 30 day currently enrol noninterventional clinical trial baseline visit potentially confound trial Prior current medical condition would prevent subject safely participate trial Undergone inpatient hospitalization within 30 day baseline visit Is undergoing apparent pubertal growth spurt Has uncontrolled hypertension History substance abuse within year baseline visit likely uncompliant History heart transplantation current placement wait list heart transplant For subject ICD : know occurrance ICD discharge 3 month prior baseline visit For subject without ICD : expect undergo implantation ICD conduct study Currently receive treatment chemotherapeutic agent immunosuppressant agent receive prior radiation therapy chest Recipient stem cell gene therapy currently treat therapeutic investigational device</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Barth Syndrome</keyword>
	<keyword>elamipretide</keyword>
	<keyword>MTP-131</keyword>
	<keyword>Stealth</keyword>
	<keyword>Stealth BT</keyword>
	<keyword>BTHS</keyword>
</DOC>